Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01703260 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

A Phase 2 study, sponsored by AstraZeneca.

Terminated
Registry status
Phase 2
Development phase
20
Enrollment target

NCT01703260: Clinical Trial Phase 2 study, sponsored by AstraZeneca.

NCT01703260 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01703260, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.

TERMINATED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the effect of roflumilast and pioglitazone therapy on serum transaminase (ALT) levels in adults with Nonalcoholic SteatoHepatitis.

Interventions

  • DRUG Placebo
  • DRUG Roflumilast
  • DRUG Pioglitazone

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2013-06
Est. Completion 2014-09
Phase Phase 2
AstraZeneca

1,285 total trials

Why NCT01703260 stopped before completion

NCT01703260 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01703260 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01703260 about?

NCT01703260 is a clinical study titled "Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis". The purpose of this study is to evaluate the effect of roflumilast and pioglitazone therapy on serum transaminase (ALT) levels in adults with Nonalcoholic SteatoHepatitis.

What is the current status of trial NCT01703260?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-06. Estimated completion is 2014-09.

What interventions are being tested in trial NCT01703260?

The interventions under investigation include: Placebo (DRUG), Roflumilast (DRUG), Pioglitazone (DRUG).

Who is sponsoring clinical trial NCT01703260?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01703260's enrollment target sits among peer trials

20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01703260, the US trial registry maintained by the National Library of Medicine. NCT01703260 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.